RESUMEN
Toxoplasma gondii is an obligatory intracellular parasite, which can infect all warm-blooded animals including humans. Cytokines, including IL-15 and IL-7, play a critical role in the regulation of the homeostasis of naive and memory T cells. Co-administration the DNA vaccine with cytokines may improve its efficacy. IL-7 and IL-15 from splenic tissues of Kunming mice were cloned, and eukaryotic plasmid pVAX-IL-7-IL-15 was constructed. Kunming mice were administrated with DNA vaccine expressing T. gondii calcium-dependent protein kinase 1 (TgCDPK1), pVAX-CDPK1, in the presence or absence of IL-7 and IL-15 plasmids (pVAX-IL-7-IL-15), immune responses were analyzed including lymphoproliferative assay, cytokine and serum antibody measurements, flow cytometric surface markers on lymphocytes, and thus protective immunity against acute and chronic T. gondii infection was estimated. Mice injected with pVAX-CDPK1 supplemented with pVAX-IL-7-IL-15 showed higher Toxoplasma-specific IgG2a titers, Th1 responses associated with the production of IFN-γ, IL-2 as well as cell-mediated cytotoxic activity where stronger frequencies of IFN-γ secreting CD8+ and CD4+ T cells (CD8+/CD4+ IFN-γ+ T cells) compared to controls. Co-administration of pVAX-IL-7-IL-15 and pVAX-CDPK1 significantly (P < 0.05) increased survival time (18.07 ± 5.43 days) compared with pVAX-CDPK1 (14.13 ± 3.85 days) or pVAX-IL-7-IL-15 (11.73 ± 1.83 days) alone, and pVAX-IL-7-IL-15 + pVAX-CDPK1 significantly reduced the number of brain cysts (73.5%) in contrast to pVAX-CDPK1 (46.0%) or pVAX-IL-7-IL-15 alone (45.0%). Our results indicate that supplementation of DNA vaccine with IL-7 and IL-15 would facilitate specific humoral and cellular immune responses elicited by DNA vaccine against acute and chronic T. gondii infection in mice.
Asunto(s)
Interleucina-15/administración & dosificación , Interleucina-7/administración & dosificación , Vacunas Antiprotozoos/normas , Toxoplasma/inmunología , Toxoplasmosis/prevención & control , Vacunas de ADN/normas , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/normas , Animales , Anticuerpos Antiprotozoarios/biosíntesis , Anticuerpos Antiprotozoarios/sangre , Línea Celular , Femenino , Inmunidad Celular , Inmunoglobulina G/biosíntesis , Inmunoglobulina G/sangre , Interferón gamma/inmunología , Interleucina-15/genética , Interleucina-15/inmunología , Interleucina-7/genética , Interleucina-7/inmunología , Linfocitos/inmunología , Ratones , Plásmidos/administración & dosificación , Vacunas Antiprotozoos/administración & dosificación , Distribución Aleatoria , Organismos Libres de Patógenos Específicos , Bazo/citología , Bazo/inmunología , Análisis de Supervivencia , Toxoplasmosis/inmunología , Toxoplasmosis/mortalidad , Vacunas de ADN/administración & dosificaciónRESUMEN
No licensed malaria vaccine exists, in spite of intensive development efforts. We have been investigating development of a DNA vaccine to prevent malaria infection. To date, we have established a full-length cDNA expression library from the erythrocytic-stage murine malaria parasite, Plasmodium berghei. We found that immunization of mice with combined 2000 clones significantly prolonged survival after challenge infection and that splenocytes from the immunized mice showed parasite-specific cytokine production. We determined the 5'-end one-pass sequence of these clones and mapped a draft genomic sequence for P. berghei for use in screening vaccine candidates for efficacy. In this study, we annotated these cDNA clones by comparing them with the genomic sequence of Plasmodium falciparum. We then divided them into several subsets based on their characteristics and examined their protective effects against malaria infection. Consequently, we selected 104 clones that strongly induced specific IgG production and decreased the mortality rate in the early phase. Most of these 104 clones coded for unknown proteins. The results suggest that these clones represent potential novel malaria vaccine candidates.
Asunto(s)
Vacunas contra la Malaria/normas , Malaria/prevención & control , Plasmodium berghei/inmunología , Vacunas de ADN/normas , Animales , Biolística , Mapeo Cromosómico , Citocinas/metabolismo , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Femenino , Genoma de Protozoos/genética , Genoma de Protozoos/inmunología , Inmunoglobulina G/sangre , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos ICR , Plásmidos/genética , Plásmidos/inmunología , Plasmodium berghei/genética , Ratas , Ratas Wistar , Organismos Libres de Patógenos EspecíficosRESUMEN
Scientists in academia whose research is aimed at the development of a novel vaccine or approach to vaccination may not always be fully aware of the regulatory process by which a candidate vaccine becomes a licensed product. It is useful for such scientists to be aware of these processes as the development of a novel vaccine could be problematic owing to the starting material often being developed in a research laboratory under ill-defined conditions. This paper examines the regulatory process with respect to the development of a DNA vaccine. DNA vaccines present unusual safety considerations that must be addressed during preclinical safety studies, including adverse immunopathology, genotoxicity through integration into a vaccinees chromosomes, and the potential for the formation of anti-DNA antibodies.
Asunto(s)
Vacunas de ADN/normas , Animales , Anticuerpos Antinucleares/biosíntesis , Ensayos Clínicos como Asunto , Citocinas/genética , Aprobación de Drogas , Evaluación Preclínica de Medicamentos , Unión Europea , Guías como Asunto , Humanos , Concesión de Licencias , Plásmidos/genética , Plásmidos/aislamiento & purificación , Control de Calidad , Seguridad , Estados Unidos , United States Food and Drug Administration , Vacunas de ADN/efectos adversos , Vacunas de ADN/farmacología , Organización Mundial de la SaludRESUMEN
The framework for regulating DNA vaccines has been in place since the first clinical trial was initiated in the mid-1990s. American and European regulatory guidance has evolved on the basis of insights provided by ongoing preclinical and clinical studies. These include analyses of the safety of DNA vaccines in normal volunteers, and recent data concerning the tissue distribution, persistence, and integration potential of DNA plasmids.